Study of Intravenous COVI-MSC for Treatment of COVID-19-Induced Acute Respiratory Distress

NCT04903327 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

43

Enrollment

INDUSTRY

Sponsor class

Stopped Due to considerably slow enrollment, unable to reach enrollment targets

Conditions

Covid19

Interventions

BIOLOGICAL: COVI-MSC
DRUG: Placebo

Sponsor

Sorrento Therapeutics, Inc.